<DOC>
	<DOC>NCT01617200</DOC>
	<brief_summary>Participants who have completed the 6-week trial P05688 can be screened for eligibility for this 26-week extension study in which they will continue treatment. The purpose of this trial is to evaluate the long-term safety of 2.5 and 5 mg asenapine administered sublingually twice daily (BID) in schizophrenia participants. Olanzapine administered 15 mg orally once daily (QD) is used as an active control.</brief_summary>
	<brief_title>Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Completed the shortterm trial P05688, and judged by the investigator likely to benefit from continued treatment Occurrence(s) of an adverse event or other clinically significant finding(s) in the shortterm trial P05688 that would prohibit the participant's continuation into the longterm extension Clinical Global ImpressionSeverity of Illness (CGIS) score of â‰¥6 (severely psychotic) at Baseline Newly diagnosed or discovered psychiatric condition that would have excluded the participant from participation in the shortterm trial P05688</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>